Key facts
- Drug class: GLP-1 receptor agonist — a 31-amino-acid analogue of human glucagon-like peptide-1, acylated with a fatty diacid chain so it binds albumin and lasts about a week.
- Brand and developer: Wegovy, Novo Nordisk. Same molecule as Ozempic and Rybelsus, marketed under a separate label and at a higher maximum strength.
- Approval status: FDA-approved (June 2021) for chronic weight management; adolescents 12+ added in 2022; cardiovascular risk reduction added March 2024; non-cirrhotic MASH with moderate-to-advanced fibrosis added under accelerated approval.
- Route: Subcutaneous injection once weekly, via a prefilled pen. An oral semaglutide formulation for weight management has since been approved in the US.
- Evidence level: Very strong. Multiple large phase 3 randomized trials (STEP 1–8), a 17,604-patient cardiovascular outcomes trial, and a head-to-head against tirzepatide.
- Commonly reported side effects: Nausea, diarrhea, vomiting, constipation, abdominal pain, burping, fatigue. Label warnings cover pancreatitis, gallbladder disease, and thyroid C-cell tumors seen in rodents.
- Legal status: Prescription-only in the US, UK, EU and most other markets. No approved generic. Not a controlled substance.
What is Wegovy?
Wegovy is a brand name, not a molecule. The molecule is semaglutide, and Novo Nordisk sells it under three different labels: Ozempic for type 2 diabetes, Rybelsus as a daily tablet for type 2 diabetes, and Wegovy for weight management at a higher weekly strength of 2.4 mg.
That distinction matters more than it sounds. Regulators approve indications, not chemicals. Wegovy carries its own clinical trial program, its own label, its own pen with its own dose markings, and its own insurance coverage rules — all built around obesity rather than glycemic control. When people ask whether Ozempic and Wegovy are the same, the honest answer is: same active ingredient, different product.
Semaglutide itself is a 31-amino-acid peptide modeled on native human GLP-1, with two substitutions that block enzymatic breakdown and a C18 fatty diacid side chain that makes it bind reversibly to albumin. Native GLP-1 has a half-life of a couple of minutes. Semaglutide's is about a week, which is the entire reason a weekly injection is possible.
Is Wegovy FDA approved, and for what?
Yes, and the list of approved uses has grown four times since launch:
- June 2021 — chronic weight management in adults with a BMI of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity, alongside reduced calorie intake and increased physical activity.
- December 2022 — adolescents aged 12 and older with obesity, following the STEP TEENS trial.
- March 2024 — cardiovascular risk reduction in adults with established cardiovascular disease and either overweight or obesity, based on the SELECT trial.
- Non-cirrhotic MASH (metabolic dysfunction-associated steatohepatitis) with moderate to advanced fibrosis, granted under accelerated approval on the basis of the ESSENCE trial's histology endpoints, with confirmatory outcome data still pending.
It is prescription-only everywhere it is licensed. It is not a controlled substance, and it is not a research chemical — a distinction worth keeping in mind when you see vials marketed online. If you are trying to work out where any given compound sits on that spectrum, our overview of peptide legal status lays out the categories.
How does Wegovy work?
GLP-1 is an incretin hormone secreted by intestinal L-cells after a meal. Its physiology is well characterized: it stimulates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and acts on hypothalamic and brainstem circuits that regulate appetite and satiety (PubMed 17928588).
For weight loss specifically, the central effect appears to do most of the work. Semaglutide crosses into brain regions that lack a tight blood-brain barrier and engages GLP-1 receptors involved in reward and food intake, which is why participants consistently report reduced appetite, earlier fullness, and less preoccupation with food. Slowed gastric emptying contributes early on but attenuates with continued exposure. The broader class pharmacology, including why some agents in it are more potent than others, is covered in our guide to GLP-1 receptor agonists and in the literature on peptide hormones that regulate appetite (PubMed 34067710).
Does Wegovy actually work? The STEP program
The evidence base is unusually deep. STEP (Semaglutide Treatment Effect in People with obesity) is a family of phase 3 randomized controlled trials, each testing semaglutide 2.4 mg weekly in a different population or against a different comparator.
STEP 1 is the headline trial: 1,961 adults with a BMI of 30 or above (or 27 with a comorbidity) and no diabetes, randomized 2:1 to semaglutide or placebo for 68 weeks with lifestyle counseling in both arms. Mean weight change was −14.9% with semaglutide versus −2.4% with placebo. About 86% of the treatment group lost at least 5% of body weight, 69% lost at least 10%, and roughly half lost 15% or more (PubMed 33567185). Those figures reset expectations for what a drug could do in obesity; the previous best-in-class, liraglutide 3.0 mg, had produced roughly 8% (PubMed 26132939).
STEP 2 tested the same dose in adults who also had type 2 diabetes, and the result is the single most under-reported number in this whole space: mean weight loss was −9.6% versus −3.4% on placebo (PubMed 33667417). People with type 2 diabetes reliably lose less on GLP-1 therapy than people without it, across every agent studied.
| Trial | Population | Duration | Weight change (semaglutide) | Comparator |
|---|---|---|---|---|
| STEP 1 | Adults with obesity/overweight, no diabetes (n=1,961) | 68 weeks | −14.9% | −2.4% placebo |
| STEP 2 | Adults with overweight/obesity and type 2 diabetes | 68 weeks | −9.6% | −3.4% placebo |
| STEP 3 | Adults plus intensive behavioral therapy | 68 weeks | −16.0% | −5.7% placebo |
| STEP 4 | Randomized after a 20-week run-in (−10.6%) | 48 more weeks | −7.9% further | +6.9% regain on placebo |
| STEP 5 | Adults with obesity/overweight (n=304) | 104 weeks | −15.2% | −2.6% placebo |
| STEP 8 | Head-to-head vs liraglutide 3.0 mg daily | 68 weeks | −15.8% | −6.4% liraglutide |
| STEP TEENS | Adolescents 12 to <18 with obesity | 68 weeks | −16.1% BMI | +0.6% BMI placebo |
| SURMOUNT-5 | Head-to-head vs tirzepatide | 72 weeks | −13.7% | −20.2% tirzepatide |
STEP 3 added intensive behavioral therapy on top of the drug and produced the largest STEP figure, −16.0% versus −5.7% (PubMed 33625476). STEP 5 extended follow-up to 104 weeks and found −15.2% versus −2.6%, showing that the loss is durable while treatment continues rather than deepening indefinitely (PubMed 36216945). STEP 8 put semaglutide directly against liraglutide 3.0 mg and won decisively, −15.8% versus −6.4%, with fewer discontinuations (13.5% versus 27.6%) (PubMed 35015037). STEP TEENS reported a −16.1% change in BMI in adolescents against +0.6% on placebo (PubMed 36322838).
One caveat worth stating plainly: these are trial means, and the spread around them is wide. A meaningful minority of participants in every STEP trial lost little or nothing.
The titration schedule used in the trials
Every STEP trial used the same stepped escalation, and it is reported here purely to describe how the studies were run — not as guidance for anyone's own use. Participants started at 0.25 mg once weekly and moved up every four weeks through 0.5 mg, 1.0 mg and 1.7 mg, reaching the 2.4 mg maintenance dose at week 16. The escalation exists to blunt gastrointestinal adverse effects, which cluster around each step up. Trials permitted slower escalation or a dose hold when tolerability was poor.
This 16-week ramp is why the "how long does it take to work" question has an awkward answer. A person is only four months into treatment when they first reach the studied maintenance dose, and the STEP 1 weight curve was still descending at week 60. Anyone tracking their own course needs a way to remember which week they are in — which is exactly the kind of thing a structured medication log is for.
SELECT: does Wegovy reduce heart attacks and strokes?
SELECT is the trial that changed how obesity medicine is reimbursed. It randomized 17,604 adults aged 45 or older with established cardiovascular disease and a BMI of 27 or above, but without diabetes, to semaglutide 2.4 mg or placebo on top of standard care, and followed them for a mean of about 40 months.
The primary composite endpoint — cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke — occurred in 6.5% of the semaglutide group versus 8.0% on placebo, a hazard ratio of 0.80 (95% CI 0.72–0.90, P<0.001) (PubMed 37952131). That is a 20% relative risk reduction and roughly 1.5 percentage points in absolute terms over more than three years.
The result did two things. It gave Wegovy a cardiovascular indication in March 2024, and it gave payers a reason to cover a weight-loss drug as cardiovascular prevention rather than as a cosmetic expense. Notably, the cardiovascular benefit did not track neatly with the amount of weight lost, which has left an open question about how much of the effect is weight-mediated and how much is direct.
Separately, the ESSENCE trial tested semaglutide 2.4 mg in 1,197 people with biopsy-confirmed MASH and stage 2–3 fibrosis. At the 72-week interim analysis, 62.9% of the semaglutide group achieved resolution of steatohepatitis without worsening fibrosis versus 34.3% on placebo, with mean weight change of −10.5% versus −2.0% (PubMed 40305708).
Wegovy side effects reported in trials
Gastrointestinal effects are the story. Across STEP, roughly three-quarters to four-fifths of participants on semaglutide reported at least one GI adverse event: nausea, diarrhea, vomiting, constipation, abdominal pain, burping, reflux. In STEP 5, GI events occurred in 82.2% of the semaglutide arm versus 53.9% on placebo, and the great majority were mild to moderate and transient, concentrated around dose escalation.
They are not trivial, though. Roughly 7% of STEP 1 participants discontinued semaglutide because of adverse events, and pooled analyses across semaglutide trials have reported adverse-event discontinuation rates around 17% versus 8% on placebo depending on the population and dose. Gallbladder-related events, most commonly cholelithiasis, were more frequent on semaglutide than placebo — an expected consequence of both rapid weight loss and reduced gallbladder motility.
Label warnings that clinicians screen for include acute pancreatitis, diabetic retinopathy complications in people with type 2 diabetes, acute kidney injury secondary to dehydration from vomiting or diarrhea, and a boxed warning for thyroid C-cell tumors based on rodent studies. Wegovy is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN2. Rapid weight loss also reduces lean mass — a consistent finding across the class, and an argument for resistance training and adequate protein that appears in nearly every clinical review.
What happens when you stop Wegovy?
Weight comes back. This is the most reproducible finding in the entire program, and the one most often glossed over in marketing.
The STEP 1 trial extension followed 327 participants for a year after both the drug and the lifestyle intervention were withdrawn. They regained about two-thirds of the weight they had lost, and cardiometabolic improvements — blood pressure, lipids, HbA1c, C-reactive protein — reverted toward baseline in parallel (PubMed 35441470).
STEP 4 was designed to test the same question prospectively. After a 20-week run-in during which everyone reached 2.4 mg and lost a mean 10.6%, participants were randomized either to continue or to switch to placebo. Over the next 48 weeks the continuation group lost a further 7.9%; the placebo group gained 6.9% (PubMed 33755728).
The clinical framing that follows is that obesity behaves like a chronic condition and semaglutide behaves like an antihypertensive: it works while you take it. That reframing has real financial and adherence implications, and it is the single most important thing to understand before starting. The same pattern shows up with tirzepatide and across the wider category covered in our review of peptides studied for weight loss.
Who is eligible for Wegovy?
The US label defines eligibility by BMI plus comorbidity, not by a desire to lose weight:
- Adults with BMI ≥30 kg/m², or BMI ≥27 kg/m² with at least one weight-related condition such as hypertension, type 2 diabetes, dyslipidemia or obstructive sleep apnea.
- Adolescents aged 12 and older with an initial BMI at or above the 95th percentile for age and sex.
- For the cardiovascular indication, adults with overweight or obesity and established cardiovascular disease.
Contraindications include a personal or family history of medullary thyroid carcinoma, MEN2, prior serious hypersensitivity to semaglutide, and pregnancy. Insurers frequently layer on additional requirements — documented prior weight-loss attempts, participation in a lifestyle program, prior authorization, step therapy through a cheaper agent. Formulary criteria are usually stricter than the label.
How much does Wegovy cost?
The US list price has sat in the region of $1,300–$1,350 per month, but that number is largely fictional in practice. Novo Nordisk sells directly to cash-paying patients through its own NovoCare Pharmacy channel at a few hundred dollars per month, with lower introductory pricing on starter strengths, and offers savings cards that can reduce commercially insured copays substantially. Medicare's treatment of anti-obesity medication has been in flux, with a time-limited coverage demonstration introduced in 2026.
Pricing in this category changes faster than any article can track. Treat every figure above as a snapshot, verify current terms with the manufacturer and your insurer, and factor in that trial evidence points to indefinite treatment rather than a finite course. Outside the US, national pricing and reimbursement differ enormously; in the UK, for example, access has been rationed through specialist weight-management services.
Wegovy vs Ozempic vs Zepbound
Three questions come up constantly, so here they are directly.
Wegovy vs Ozempic. Same molecule, different indication and different ceiling: Ozempic is licensed for type 2 diabetes and tops out at 2 mg weekly, Wegovy is licensed for weight management and cardiovascular risk reduction at 2.4 mg. Prescribing Ozempic purely for weight loss is off-label. The full breakdown is in our Ozempic vs Wegovy comparison.
Wegovy vs Zepbound (tirzepatide). SURMOUNT-5 was the first head-to-head randomized trial: tirzepatide produced −20.2% at 72 weeks versus −13.7% for semaglutide 2.4 mg, with waist circumference falling 18.4 cm versus 13.0 cm (PubMed 40353578). Tirzepatide is a dual GIP/GLP-1 agonist and is more potent for weight; semaglutide has the stronger cardiovascular outcomes evidence. See tirzepatide vs semaglutide and Mounjaro for the diabetes-labeled version of the same molecule.
Wegovy vs the rest of the class. Head-to-head comparisons across GLP-1 receptor agonists have been systematically reviewed, and semaglutide consistently sits at the top of the mono-agonist group (PubMed 33767808). Newer combinations such as cagrilintide plus semaglutide, and triple agonists, are pushing the ceiling higher still.
Frequently asked questions
Is Wegovy the same thing as Ozempic?
Both are semaglutide made by Novo Nordisk, but they are separate products with separate approvals. Ozempic is approved for type 2 diabetes at strengths up to 2 mg weekly. Wegovy is approved for chronic weight management, cardiovascular risk reduction and MASH, and reaches 2.4 mg weekly. The pens, labels, maximum strengths and insurance coverage rules differ.
How much weight do people lose on Wegovy?
In STEP 1, 1,961 adults without diabetes lost a mean of 14.9% of body weight over 68 weeks versus 2.4% on placebo. About 86% lost at least 5% and roughly half lost 15% or more. Results are lower in people with type 2 diabetes: STEP 2 reported a mean 9.6% loss versus 3.4% on placebo. Individual results vary widely.
How long does Wegovy take to work?
Appetite effects often appear within the first weeks, but trial weight curves keep falling for roughly a year. In STEP 1 the average weight loss curve did not flatten until around week 60 of 68. STEP 5 followed people for 104 weeks and found weight loss was largely maintained rather than continuing to deepen after year one.
What are the most common Wegovy side effects?
Gastrointestinal effects dominate: nausea, diarrhea, vomiting, constipation, abdominal pain, burping and reflux. In STEP 5, 82.2% of the semaglutide group reported a gastrointestinal event versus 53.9% on placebo, and most were mild to moderate and clustered around dose escalation. Gallbladder disease, pancreatitis and, in animal studies, thyroid C-cell tumors are label warnings.
Do you regain weight after stopping Wegovy?
Usually, yes. The STEP 1 trial extension followed participants for a year after the drug and lifestyle program were withdrawn and found they regained about two-thirds of the weight they had lost, with blood pressure, lipids and glycemic markers drifting back toward baseline. STEP 4 showed the same pattern faster: switching to placebo produced 6.9% regain over 48 weeks.
Is Wegovy FDA approved?
Yes. Wegovy was approved by the FDA in June 2021 for chronic weight management in adults, extended to adolescents aged 12 and older in 2022, given a cardiovascular risk reduction indication in March 2024 on the strength of the SELECT trial, and later approved for non-cirrhotic MASH with moderate to advanced fibrosis under accelerated approval. It is prescription-only.
Who is eligible for Wegovy?
The US label covers adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition such as hypertension, type 2 diabetes or dyslipidemia, plus adolescents 12 and older at the 95th BMI percentile or above. The cardiovascular indication applies to people with established cardiovascular disease and overweight or obesity. A prescriber decides.
Is Wegovy or Zepbound more effective for weight loss?
In SURMOUNT-5, the first head-to-head randomized trial, tirzepatide produced a mean 20.2% weight reduction at 72 weeks versus 13.7% for semaglutide 2.4 mg. Tirzepatide also reduced waist circumference more, by 18.4 cm versus 13.0 cm. Semaglutide, however, has the larger cardiovascular outcomes dataset behind it from the SELECT trial.
How much does Wegovy cost without insurance?
US list price has been roughly 1,300 to 1,350 dollars per month, but almost nobody pays it. Novo Nordisk sells directly to cash-paying patients through NovoCare Pharmacy at a few hundred dollars per month, and commercial insurance with a savings card can bring copays far lower. Prices, program terms and Medicare rules change often, so check current figures.
Can you buy Wegovy or generic semaglutide online?
Wegovy is a prescription-only branded product with no approved generic, and semaglutide remains under patent. Research-grade vials sold online as semaglutide are not FDA-approved medicines, are not manufactured to pharmaceutical standards and have been linked to dosing errors and adverse events. Legitimate access runs through a licensed prescriber and a licensed pharmacy.
Sources
Every claim above traces to peer-reviewed literature indexed on PubMed:
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) — PubMed 33567185
- Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2) — PubMed 33667417
- Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight: The STEP 3 Randomized Clinical Trial — PubMed 33625476
- Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance: The STEP 4 Randomized Clinical Trial — PubMed 33755728
- Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial — PubMed 36216945
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight: The STEP 8 Randomized Clinical Trial — PubMed 35015037
- Once-Weekly Semaglutide in Adolescents with Obesity (STEP TEENS) — PubMed 36322838
- Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension — PubMed 35441470
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) — PubMed 37952131
- Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis (ESSENCE) — PubMed 40305708
- Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5) — PubMed 40353578
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management — PubMed 26132939
- GLP-1 receptor agonists: an updated review of head-to-head clinical studies — PubMed 33767808
- The physiology of glucagon-like peptide 1 — PubMed 17928588
- The Role of Peptide Hormones Discovered in the 21st Century in the Regulation of Appetite and Metabolism — PubMed 34067710